IPIris Paltin

Iris Paltin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iris Paltin has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessing Cognitive Functioning in Children With Brain Tumors: Interaction of Neighborhood Social Determinants of Health and Neurological Risk

    by Alannah R. Srsich, Manali Zope, Peter M. Fantozzi, Cassie N. Kline, Iris Paltin, Matthew C. Hocking

    Background: This study investigated how neighborhood‐level social determinants of health (SDOH), including redlining and neurological risk, interact to influence cognitive outcomes in children treated for brain tumors (CTBT). Methods: A retrospective chart review of 161 CTBT aged 5–17 was conducted. Cognitive outcomes were measured using standardized neuropsychological assessments, and SDOH were assessed using the Childhood Opportunity Index (COI) and redlining data. The Neurological Predictor Scale (NPS) measured treatment‐related neurological risk. Results: Compared to moderate and high‐opportunity neighborhoods, children in low‐opportunity neighborhoods exhibited lower intellectual functioning (IF) (F [2, 154] = 17.7, p < 0.01, η 2 = 0.19), processing speed ( F [2, 89] = 4.41, p = 0.015, η 2 = 0.09), perceptual reasoning ( F [2, 64] = 3.60, p = 0.03, η 2 = 0.10), and verbal reasoning ( F [2, 90] = 10.09, p < 0.01, η 2 = 0.18) scores. COI moderated the association between NPS and IF( F [2, 147] = 4.47, p = 0.013), with a negative effect of NPS on IF in high‐opportunity neighborhoods ( t = − 3.82, p < 0.01). Children from neighborhoods less affected by redlining demonstrated better IF performance, U = 94.50, Z = −2.30, p = 0.021. Conclusions: The findings highlight the importance of considering both treatment‐related neurological burden and neighborhood‐level SDOH when evaluating cognitive outcomes in CTBT. Survivors from lower opportunity environments demonstrated the highest rates of cognitive impairment, whereas the interaction between neurological risk and outcomes was significant only among youth from high‐opportunity neighborhoods. These results support a risk‐informed approach to survivorship care that considers both contextual and medical factors.


  • Neuropsychological Late Effects and Quality-of-Life Outcomes in Pediatric Brain Tumor Survivors: Role of Pediatric Neurologists in Monitoring and Management

    by Iris Paltin, Megan Sy, Shannon M. Lundy, Lauren K. Ayr-Volta, Rebecca Canale, Grace Fong, Kelly Janke, Gina B. Pfeifle, Thea Quinton, Hannah-Lise Schofield, et al.


  • Open Access

    48 Longitudinal Language Outcomes in Pediatric Brain Tumor Patients Diagnosed in Early Childhood

    by Iris Paltin, Mariam Kochashvili, Megan Sy, Hannah-Lise Schofield, Zoe Kearns, Kelly Janke

    Objective:Pediatric brain tumor (PBT) survivors are at risk for speech (e.g., articulation, prosody, fluency) and language (e.g., vocabulary, grammar, narratives, pragmatics) difficulties (Hodges et al., 2020). It is important to understand what treatment and/or demographic factors are associated with language functioning soon after diagnosis, and what factors are associated with language functioning years after treatment completion. This study characterizes longitudinal language functioning for clinically referred PBT survivors diagnosed in early childhood.Participants and Methods:Participants were 48 PBT patients (54% supratentorial, 6% disseminated), 21% with NF-1, who were diagnosed by age 6 (M = 43.2 months, SD 24.5) and received tumor-directed intervention including surgery (85%), chemotherapy (69%), and/or radiation therapy (50%). Hearing concerns existed for 29% of the patients. Age at first neuropsychological evaluation was 2-15 years (M=7.6, SD=3.63), age at second neuropsychological evaluation was 5-19 years (M=12.04, SD=3.86), with an average of 4.42 years (SD=2.37) between evaluations. Patients were 63% male, 77% White, 94% non-Hispanic, and fluent English speakers. Verbal IQ, working memory, fluencies, comprehension, memory, and parent-reported functional communication outcomes were assessed as part of comprehensive batteries. Rates of weak performance (1 SD<Mean) were compared to the expected base rate of 16%.Results:Group means significantly diverged from age-expected performance by the second evaluation in all domains except semantic fluency. Weakness was identified on at least 1 verbal subtest for 79% of the sample at the first evaluation, and for 85% of the sample at the second evaluation. As a group, patients showed a significant increase in the number of weaknesses identified on performance-based measures from the first to second evaluation [t(47) = -3.60, p <.001]. Over half of the sample showed an increase in the rate of verbal weaknesses identified (56.3%). Those with more weaknesses over time had lower IQ at the initial evaluation [t(36) =-2.61, p=.013]. An increase in the number of weaknesses from first to second evaluation was not associated with tumor type/location, treatment modality, or demographic variables.Conclusions:Brain tumor diagnosis in early childhood during rapid language development is associated with language impairments soon after diagnosis, and years after treatment completion. Causes for continued and increased impairment are multifactorial and risk cannot clearly be identified by demographic and treatment variables alone. Any early language weakness identification should signal need for intervention as the causes for difficulty are complex and these weaknesses are likely to persist and increase over time.


  • Open Access

    Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1

    by Karin S. Walsh, Pamela L. Wolters, Brigitte C. Widemann, Allison del Castillo, Maegan D. Sady, Tess Inker, Marie Claire Roderick, Staci Martin, Mary Anne Toledo-Tamula, Kari Struemph, et al.

    Background and Objectives Neurofibromatosis type 1 (NF1)-associated cognitive impairments carry significant lifelong morbidity. The lack of targeted biologic treatments remains a significant unmet need. We examine changes in cognition in patients with NF1 in the first 48 weeks of mitogen-activated protein kinase inhibitor (MEKi) treatment. Methods Fifty-nine patients with NF1 aged 5–27 years on an MEKi clinical trial treating plexiform neurofibroma underwent pretreatment and follow-up cognitive assessments over 48 weeks of treatment. Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were the primary outcomes. Group-level (paired t tests) and individual-level analyses (Reliable Change Index, RCI) were used. Results Analysis showed statistically significant improvements on BRIEF compared with baseline (24-week Behavioral Regulation Index: t(58) = 3.03, p = 0.004, d = 0.24; 48-week Metacognition Index: t(39) = 2.70, p = 0.01, d = 0.27). RCI indicated that more patients had clinically significant improvement at 48 weeks than expected by chance (χ2 = 11.95, p = 0.001, odds ratio [OR] = 6.3). Group-level analyses indicated stable performance on Cogstate (p > 0.05). RCI statistics showed high proportions of improved working memory (24-week χ2 = 8.36, p = 0.004, OR = 4.6, and 48-week χ2 = 9.34, p = 0.004, OR = 5.3) but not visual learning/memory. Patients with baseline impairments on BRIEF were more likely to show significant improvement than nonimpaired patients (24 weeks 46% vs 8%; χ2 = 9.54, p = 0.008, OR = 9.22; 48 weeks 63% vs 16%; χ2 = 7.50, p = 0.02, OR = 9.0). Discussion Our data show no evidence of neurotoxicity in 48 weeks of treatment with an MEKi and a potential clinical signal supporting future research of MEKi as a cognitive intervention.